Phibro Animal Health reports record FY2026 results, raises FY2027 guidance

PHIBRO ANIMAL HEALTH CORP

2026-FY EPS reported $2.43 revenue$1,518,093,000

Q4 net sales $396.7M (+5% YoY); diluted EPS $0.53 (+26%); adjusted EPS $0.85 (+35%).
FY2026 net sales $1,518.1M (+17%); net income $99.7M; adjusted EBITDA $255.0M (+39%).
FY2027 guidance: net sales $1.55-1.60B, adjusted EBITDA $258-268M, adjusted net income $140-147M.
Plans to close Chicago Heights manufacturing facility; production ceases summer 2027, ~100 employees affected.
Regulatory uncertainty on virginiamycin in Brazil; guidance assumes minimal sales, potential upside if approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.